Innovative biopharmaceutical companies are increasingly engaging in strategic partnerships with CDMOs, whereas in the past, these companies relied more on transactional and fee-for-service relationships.
SyrHA was able to see at CPHI Barcelona 2023 that the expectations of biopharmaceutical customers are increasing.
All issues are concerned: the resolution of development and manufacturing challenges, the care given to quality, the respect of increasingly short deadlines and the rigor of delivery.
For their part, CDMOs are looking to expand their capabilities and enrich their services to support their customers from one end of the chain to the other.
Isn’t there a scattering of skills in this race to lengthen the list of services offered? A loss of identity and true value of CDMOs?
Could we see the emergence of CRDMOs, merging services provided by CROs, CDOs, CMOs and CPOs, which were historically fragmented?
Other CDMOs, such as SyrHA, prefer to play the expertise card: supporting their clients on a short list of subjects but in a totally controlled way. Leaving the issues of regulatory registration and packaging to the service providers whose job it is.
Specialize in a single form of medical currency, in a few areas of activity, and in one or two types of molecule.
At SyrHA, we support you on all your healthcare projects in the form of a pre-filled syringe. Our expertise covers the fields of aesthetics, orthopedics, ophthalmics, ophthalmology and dermatology.
We design your hydrogel products in Switzerland and manufacture them in France.
At SyrHA, one molecule reigns supreme: Hyaluronic acid, but our catalog is not limited to it.
Contact us and discover our ready-to-use product portfolio.
Do you have a unique development project? Write to us, we’d love to hear more.
